Mineralys (MLYS) Insider Plans Sale of 11,367 Shares via Merrill Lynch

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) Form 144 shows a proposed sale of 11,367 shares of common stock via Merrill Lynch with an aggregate market value of $409,266.28, to be sold approximately on 09/15/2025 on NASDAQ. The filer reports acquiring those shares by exercising employee stock options on 09/11/2024 (5,018 shares) and 09/12/2024 (6,349 shares), with cash payment on the acquisition dates. The filing lists 66,295,184 shares outstanding. The document also discloses two recent sales by the same person: 11,365 shares sold on 08/13/2025 for $146,987.47 and 11,366 shares sold on 07/14/2025 for $165,878.90. The broker named is Merrill Lynch, 225 Liberty St, New York.

Positive

• Disclosure compliance: The filer provided required Form 144 details including broker, number of shares, market value, and acquisition history.
• Source of shares clear: Shares were acquired via employee stock option exercises with cash paid, clarifying provenance for Rule 144 resale.

Negative

• Insider selling activity: The same person recorded recent sales in July and August 2025, indicating continued disposition of holdings.

Insights

Securities Analyst

TL;DR: Insider intends to sell recently exercised shares totaling 11,367, indicating monetization of stock options rather than an acquisition by purchase.

The filing documents an insider sale notice under Rule 144 for 11,367 shares valued at $409,266.28, with the shares acquired through exercise of employee stock options in September 2024 and paid in cash on the exercise dates. Two prior transfers by the same individual in July and August 2025 appear in the record as sales, showing recent liquidity events. This is a routine regulatory notice to enable public resale under Rule 144 and does not by itself disclose new operational or financial information about the issuer.

Corporate Governance Expert

TL;DR: The Form 144 is a standard disclosure of proposed insider sales; it confirms compliance steps but reveals continued insider selling activity.

The report names a broker and sets an approximate sale date, meeting procedural requirements for Rule 144 resale. It documents source of shares as option exercises and affirms cash payment at exercise. The inclusion of recent sales in July and August 2025 highlights ongoing disposition of holdings by the same person. No material undisclosed corporate information is provided in the filing text.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	11367	409266.28	66295184	09/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	09/11/2024	Exercise of employee stock options	Mineralys Therapeutics, Inc.			5018	09/11/2024	Cash
Common stock	09/12/2024	Exercise of employee stock options	Mineralys Therapeutics, Inc.			6349	09/12/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	08/13/2025	11365	146987.47
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	07/14/2025	11366	165878.90

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is being reported in the Form 144 for MLYS?

The Form 144 reports a proposed sale of 11,367 shares of common stock valued at $409,266.28, to be sold approximately on 09/15/2025 on NASDAQ.

How were the shares to be sold acquired according to the filing?

The shares were acquired by exercising employee stock options on 09/11/2024 (5,018 shares) and 09/12/2024 (6,349 shares), with cash payment on those dates.

Who is the broker handling the proposed sale?

The broker listed is Merrill Lynch, 225 Liberty St Floor 37, New York, NY 10281.

Does the filing show any recent sales by the same person?

Yes. The filing discloses sales of 11,365 shares on 08/13/2025 for $146,987.47 and 11,366 shares on 07/14/2025 for $165,878.90.

How many shares outstanding does the filing report?

The filing reports 66,295,184 shares outstanding.